Apollomics to Present at 2024 BIO International Convention

FOSTER CITY, Calif., May 29, 2024 – Apollomics Inc. (Nasdaq: APLM), a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments, is set to present at the 2024 BIO International Convention from June 3-6 in San Diego, California. This event will provide an opportunity for Apollomics to showcase its advancements in oncology therapies.

The presentation by Apollomics is scheduled for Tuesday, June 4, 2024, at 3:15 p.m. It will take place in Theater 2, located in Hall A of the Exhibition Hall at the San Diego Convention Center. Dr. Sanjeev Redkar, President and Executive Director of Apollomics, will lead the presentation, providing insights into the company’s progress and future directions.

During the convention, Apollomics’ management team will be available for one-on-one meetings with registered attendees. Interested parties can arrange these meetings through the BIO One-on-One Partnering™ system.

Apollomics Inc. is dedicated to discovering and developing oncology treatments that can be combined with other therapies to harness the immune system and target specific molecular pathways to inhibit cancer growth. The company boasts a pipeline of nine drug candidates across multiple programs, with six currently in the clinical stage of development. Among its leading programs are vebreltinib (APL-101) and uproleselan (APL-106).

Vebreltinib (APL-101) is a potent and selective c-Met inhibitor aimed at treating non-small cell lung cancer and other advanced tumors with c-Met alterations. Uproleselan (APL-106), on the other hand, is a specific E-Selectin antagonist designed to be used adjunctively with standard chemotherapy for the treatment of acute myeloid leukemia.

Both of these lead programs exemplify Apollomics’ approach to developing targeted oncology therapies that not only attack cancer cells directly but also support the body’s immune system in fighting the disease.

This announcement underscores Apollomics’ ongoing commitment to advancing cancer treatment through innovative biopharmaceutical solutions. The upcoming BIO International Convention will serve as a platform for the company to highlight its latest research and development efforts to a global audience of industry experts and potential partners.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!